Canine distemper virus (CDV) is dangerous. CDV is known for high morbidity and mortality rates, wide geographic distribution and high rate of contagion.¹

AAHA recommends …
All puppies be vaccinated for CDV, with revaccination one year after the initial series. RECOMBITEK distemper vaccine is approved for all dogs, including those in shelter situations.³

Advanced recombinant canarypox-vectored technology makes the difference.
RECOMBITEK Distemper vaccine:
• Uses no whole or live CDV — no reversion to virulence, no risk of shedding, no post-vaccinal distemper encephalitis
• Was shown in a study to permit no interference from circulating CDV antibodies³
• In the same study, was shown to work in puppies with no interference from maternal antibodies³
• Is more likely than an MLV vaccine to produce a significant anamnestic response in previously vaccinated dogs⁴
• Does not demonstrate immunosuppression seen with MLV-CDV combination vaccines.⁵,⁶

Onset of immunity within 15 minutes.
Proven in a study, CDV-antibody-negative puppies vaccinated with RECOMBITEK C6 15 minutes prior to a virulent intravenous challenge were free of clinical signs of CDV infection four weeks later.⁷

Proven protection within four hours.
In the same study, CDV-antibody-negative puppies vaccinated with RECOMBITEK C6 four hours before exposure to CDV-infected dogs in a shelterlike setting showed no signs of distemper infection for four weeks.⁷

Significantly more dogs receiving RECOMBITEK C4 developed an increase** in CDV antibody titer.*

Vaccines
A - Merial RECOMBITEK C4
B - Schering-Plough Animal Health GALAXY® DA, PP,
C - Ft. Dodge Animal Health DURAMUNE® Max 5
D - Pfizer Animal Health VANGUARD® 5
E - Intervet PROGARD® 5

**Defined as fourfold or greater

More dogs show significant boost in antibody titers.
After vaccination with RECOMBITEK C4, 70% to 90% of previously vaccinated dogs developed a significant increase** in CDV antibody titer. Only 10% to 35% of dogs did the same after receiving an MLV-CDV vaccine.⁴
RECOMBITEK C3 contains a lyophilized suspension of a recombinant canarypox vector expressing the HA and F glycoproteins of canine distemper virus; modified live adenovirus type 2, and parvovirus; plus sterile water diluent. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible dogs.

Indications.

RECOMBITEK C3 is recommended for the vaccination of healthy dogs 6 weeks of age and older for prevention of disease due to canine distemper virus, canine parvovirus, canine adenovirus type 1 (canine hepatitis) and canine adenovirus type 2 (canine respiratory disease complex).

Dosage.

Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject 1 mL (one dose) subcutaneously or intramuscularly into healthy dogs. For primary vaccination, revaccinate with a second 1 mL dose two to three weeks later. Dogs younger than 12 weeks of age should be revaccinated with a single 1 mL dose every two to three weeks, the last dose given at or over 12 weeks of age. Revaccinate annually with a single 1 mL dose.

Storage.

Store at 2º to 7ºC (35º to 45ºF). Use immediately after reconstitution.

Precautions.

Do not use chemicals to sterilize syringes and needles. Burn container and all unused contents. Contains gentamicin as a preservative. It is generally recommended to avoid vaccination of pregnant dogs. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Transient lethargy, as well as pain and swelling at the site of injection, may occur following use of this product. Treatment may include antihistamines, anti-inflammatories and/or epinephrine, as directed by a veterinarian.

Choose from RECOMBITEK C3, RECOMBITEK C4, RECOMBITEK C4/CV, RECOMBITEK C6 and RECOMBITEK C6/CV.

RECOMBITEK C3 product label description.*

RECOMBITEK C3 is recommended for the vaccination of healthy dogs 6 weeks of age and older for prevention of disease due to canine distemper virus, canine parvovirus, canine adenovirus type 1 (canine hepatitis) and canine adenovirus type 2 (canine respiratory disease complex).

Dosage.

Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject 1 mL (one dose) subcutaneously or intramuscularly into healthy dogs. For primary vaccination, revaccinate with a second 1 mL dose two to three weeks later. Dogs younger than 12 weeks of age should be revaccinated with a single 1 mL dose every two to three weeks, the last dose given at or over 12 weeks of age. Revaccinate annually with a single 1 mL dose.

Precautions.

Do not use chemicals to sterilize syringes and needles. Burn container and all unused contents. Contains gentamicin as a preservative. It is generally recommended to avoid vaccination of pregnant dogs. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Transient lethargy, as well as pain and swelling at the site of injection, may occur following use of this product. Treatment may include antihistamines, anti-inflammatories and/or epinephrine, as directed by a veterinarian.

To learn more about RECOMBITEK vaccines and how they can benefit your patients, contact your Merial Sales Representative or your Merial Distributor Representative or call Merial Customer Care: 1-888-Merial-1 or Visit MERIALconnect.com™

Ask your Merial Representative about our Satisfaction Guarantee on RECOMBITEK.

*RECOMBITEK distemper with recombinant canarypox-vectored vaccine technology is available in the following combinations: RECOMBITEK C2, RECOMBITEK C3, RECOMBITEK C4, RECOMBITEK C4/CV, RECOMBITEK C6 and RECOMBITEK C6/CV. For more information, please visit www.merial.com.

Because of this … You and your patients benefit this way …

| Recombinant canarypox-vectored technology | Excellent protection and freedom from the risks associated with MLV vaccines |
| No whole virus | Targeted protection; vaccine cannot cause disease it is designed to prevent |
| Safe for puppies as young as 6 weeks of age | Pre-weaning disease protection |
| In a study, shown to protect puppies in the presence of maternal antibodies | Pre-weaning disease protection |
| No interference from circulating CDV antibodies | Confidence in booster vaccinations |
| Significant anamnestic response in previously vaccinated dogs | Confidence in booster vaccinations |
| No suppression of lymphocyte responsiveness | No immunosuppression after vaccination; safe for immunocompromised puppies |
| Proven rapid onset of immunity | Confidence in protection soon after vaccination |
| AVMA recommendation for use in shelter medicine | Confidence for use in high-pressure situations |
| Humoral and cell-mediated immunity | Comprehensive immune response |
| Available in five combinations | Flexibility to fit your protocols |

**References:**


